Team - Sound Bioventures

Sound Bioventures is a venture capital fund investing in about-to-be clinical or clinical stage private companies in Europe and USA developing therapies in specialty therapeutics areas.

We lead, co-lead or follow

Team

As co-investors, you will find us straight forward, transparent, long term oriented and asking “is this the right thing to do for the company” at every step of our decision making.

Read more about the Team

Strategy & Approach

Sound Bioventures is a venture capital fund investing in about-to-be clinical or clinical stage private companies in Europe and USA developing therapies in specialty therapeutics areas.

Read more about Strategy & Approach

Introducing the team

Why the name Sound Bioventures?

Our investment firm started as a Danish-Swedish project with our Danish founder Casper Breum and our Swedish founder Johan Kördel living on either side of the stretch of water between Denmark and Sweden connecting the North and Baltic seas, called “the Sound”. The name is derived from the Scandinavian Öresund (SE) or Øresund (DK). The Sound has always been one of the world’s busiest shipping lanes with approximately 40.000 ships passing through annually. The SE/DK Sound or Greater Copenhagen region is referred to as Medicon Valley and is, like the shipping lane, arguably the busiest in Scandinavia. When our American founder Bibhash Mukhopadhyay joined, our proposition to our investors and portfolio companies took on an expanded global perspective and footprint, spanning an even bigger water passage, the Atlantic Ocean.-“a super sized version of the Sound”! Sound does of course also stand for financially robust investments as well as investments that lead to a healthy body and mind.
Read more about Sound Bioventures »

The drive to adapt a lab discovery into treatment of neurodegeneration

Teitur Trophics is breaking new ground when it comes to neurodegenerative diseases. After identifying a previously unknown means of preserving functioning brain cells, the biotech company’s founders aim to translate that discovery into therapies for conditions with almost no current treatment options. According to Co-Founder and CEO Simon Mølgaard, …
Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
Save Accept all